Vesicular Stomatitis Indiana Virus

Overview and Taxonomy of Vesicular Stomatitis Indiana Virus

1. Taxonomy and Phylogenetic Classification

Vesicular Stomatitis Indiana Virus (VSIV) is a highly significant member of the family Rhabdoviridae, genus Vesiculovirus, and represents the prototypic species now formally designated as Indiana vesiculovirus by the International Committee on Taxonomy of Viruses (ICTV) [5, 14]. Historically referred to as vesicular stomatitis virus (VSV) Indiana serotype (VSVIND or VSV-IN), the nomenclature has evolved to emphasize the distinct viral entity, which is one of two principal serotypes, alongside Vesicular Stomatitis New Jersey Virus (VSNJV), responsible for the vesicular stomatitis (VS) disease complex in livestock [7, 12, 23]. This taxonomic distinction is critical, as the two serotypes are antigenically distinct, exhibit differential epidemiological patterns, and are classified as separate species within the Vesiculovirus genus [17, 23].

Molecularly, VSIV possesses a linear, single-stranded, negative-sense RNA genome of approximately 11 kilobases, which is organized into five canonical genes in the order: 3′-N-P-M-G-L-5′ [5]. The nucleoprotein (N), phosphoprotein (P), matrix protein (M), glycoprotein (G), and large polymerase (L) together orchestrate the viral life cycle. The matrix protein, in particular, forms a bridge between the viral envelope and the ribonucleoprotein core, playing an indispensable role in viral assembly and budding [1]. In-silico analyses of the VSIV matrix protein have revealed a predominance of alpha-helical secondary structures and a stable tertiary architecture, underscoring its functional conservation [1]. The G protein, conversely, is the primary antigenic determinant responsible for receptor binding and membrane fusion, and it is the target of neutralizing antibodies; its structure defines the serotype-specific properties that differentiate VSIV from VSNJV and other vesiculoviruses such as Cocal virus and Maraba virus [14, 17].

Phylogenetically, VSIV exhibits a complex substructure comprising multiple subtypes or lineages. The prototype Indiana serotype is often referred to as Indiana 1 (VSIV-1), but serological and molecular surveys have identified additional subtypes, including Indiana 2 (VSIV-2) and Indiana 3 (VSIV-3), which circulate in distinct geographic regions of South and Central America [19, 21]. For instance, VSIV-3 has been documented in northeastern Brazil, where seroprevalence studies in horses have demonstrated high neutralizing antibody titers, indicative of active viral circulation [21]. In the United States, only VSIV-1 has been associated with epizootics, and phylogenetic analyses of full-genome sequences from the 2019–2020 outbreaks have confirmed that the epidemic lineage originated from a specific ancestral group circulating in the endemic zone of Chiapas, Mexico [2, 3, 6]. Deep sequencing and phylogenomic signatures have further resolved this lineage into at least four distinct subpopulations during its northward incursion, each characterized by specific single nucleotide polymorphisms (SNPs) [2]. The preponderance of synonymous mutations and the role of purifying selection, particularly on the P and G genes, suggest that the epidemic phenotype is highly conserved, while positive selection at specific codon sites in the P, M, G, and L proteins may facilitate adaptation to new ecological niches and vector populations [2].

2. Overview: Biological, Epidemiological, and Biotechnological Significance

VSIV is a vector-borne, zoonotic pathogen that causes an economically devastating vesicular disease in cattle, horses, and swine [12, 23]. The disease is clinically indistinguishable from foot-and-mouth disease (FMD), a fact that necessitates rapid and accurate diagnostic assays to differentiate VSIV from FMD virus, which is of paramount concern for international trade and animal health authorities such as the World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO) [5, 25].

The natural transmission cycle of VSIV involves arthropod vectors, primarily biting midges (Culicoides spp.) and black flies (Simulium spp.), which acquire the virus from infected hosts and transmit it to susceptible livestock [8, 11, 24]. The virus is maintained endemically in a defined focus extending from southern Mexico through Central America and into northern South America [12, 19, 21]. In the United States, VSIV does not persist endemically; instead, it emerges sporadically as epizootics that typically follow a biennial pattern, with incursion years characterized by virus introduction from the endemic zone, followed by overwintering in local vector or host populations and subsequent expansion in the following year [12, 15, 23]. The 2019 outbreak was the largest VS outbreak in the United States in 40 years, affecting 1,144 premises across eight states, and it was exclusively caused by VSIV, the first time this serotype had been isolated in the country since 1998 [6, 23]. In 2020, a second wave of VSIV activity spread eastward into Kansas and Missouri, regions not typically affected by VSV epizootics, suggesting an expanded geographic range potentially linked to climate-driven changes in vector distribution [11, 23, 24].

One of the most distinctive epidemiological features of VSIV is its substantially lower prevalence compared to VSNJV within the endemic range. Longitudinal surveillance data from Chiapas, Mexico, reveal that VSNJV seroprevalence in adult cattle ranges from 75% to 100%, whereas VSIV seroprevalence is less than 1% [8]. Similarly, in Costa Rica, human exposure to VSNJV is significantly higher than to VSIV, with agricultural workers and individuals with direct cattle contact being at greatest risk [10]. This disparity is mirrored in the detection of viral RNA in potential arthropod vectors: VSNJV RNA is found frequently in multiple insect taxa, while VSIV RNA is detected only rarely, primarily in mosquitoes, suggesting fundamental differences in vector competence or transmission dynamics between the two serotypes [8]. In the United States, the role of feral swine as an amplifying host appears negligible, as a large-scale serosurvey detected only a single VSIV-positive animal, indicating that feral swine do not constitute a reservoir that would sustain the virus between outbreaks [9].

The host response to VSIV infection is mediated by a robust innate immune system, with type I interferons (IFNs) playing a central role. A key interferon-stimulated gene (ISG) product, tripartite motif-containing protein 69 (TRIM69), has been identified as a potent and specific inhibitor of VSIV replication [4]. Remarkably, a single amino acid substitution in the VSIV genome can determine sensitivity or resistance to TRIM69, highlighting the evolutionary arms race between the virus and its host. TRIM69 exhibits signatures of positive selection in human populations, suggesting that this antiviral factor may influence the outcome of VSIV exposure in natural and therapeutic settings [4].

Beyond its natural pathogenicity, VSIV has become a cornerstone of molecular virology and biotechnology. Its simple genome, rapid replication kinetics, and ease of genetic manipulation have made it an indispensable tool for studying viral transcription, replication, and host-pathogen interactions [1, 5]. The VSIV G protein is the gold-standard envelope glycoprotein for pseudotyping lentiviral vectors, which are widely used in gene therapy and vaccine development [14]. Furthermore, recombinant VSIV vectors have been engineered for oncolytic virotherapy and as vaccine platforms for emerging infectious diseases, including Ebola virus, Zika virus, and HIV [13, 16, 18, 20, 22]. The live-attenuated recombinant vesicular stomatitis virus–vectored Ebola vaccine (rVSVΔG-ZEBOV-GP), which replaces the VSIV G gene with the Zaire Ebola virus glycoprotein, has demonstrated safety and immunogenicity in clinical trials and has been used for emergency postexposure prophylaxis following high-risk needlestick injuries [13, 22]. Similarly, recombinant VSIV vectors encoding human interferon beta and the sodium iodine symporter are being evaluated in phase I clinical trials for the treatment of relapsed or refractory hematologic malignancies, such as multiple myeloma and T-cell lymphoma [20]. The inherent oncolytic properties of VSIV, including its ability to selectively replicate in and lyse tumor cells, have been demonstrated against melanoma, hepatocellular carcinoma, and breast adenocarcinoma cell lines, and the Indiana serotype exhibits comparable or superior oncolytic efficiency relative to the New Jersey serotype in certain cancer models [7].

Given its dual relevance as a causative agent of a WOAH-notifiable livestock disease and as a versatile platform for medical countermeasures, an exhaustive understanding of VSIV taxonomy, evolution, and biological behavior is essential for both veterinary epidemiology and translational medicine. The taxonomic and genomic frameworks established through in-silico characterization and phylogenetic surveillance provide the foundation for diagnostic assay refinement, outbreak forecasting, and the rational design of next-generation vaccines and therapies [1, 2, 25].

Virion Architecture and Genome Organization of VSIV

Vesicular Stomatitis Indiana Virus (VSIV), the prototypic member of the genus Vesiculovirus within the family Rhabdoviridae, exhibits a virion architecture that is both exquisitely simple and remarkably sophisticated. The bullet-shaped morphology of VSIV, a hallmark of the rhabdovirus family, is the direct result of a precisely orchestrated assembly of five structural proteins and a single-stranded RNA genome, and this architecture is intimately linked to the virus’s ability to replicate, assemble, and disseminate within and between hosts. The virion, measuring approximately 180 nanometers in length and 75 nanometers in diameter, is enveloped, and its structural integrity is maintained by a helical ribonucleoprotein core and a dense matrix protein layer. The organization of the genome, an 11-kilobase negative-sense RNA molecule, dictates a strict transcriptional gradient that is essential for the differential expression of viral proteins, thereby enabling the virus to regulate its replication cycle with high fidelity. A deep understanding of this architecture and genome organization is not merely an academic exercise; it underpins the development of VSIV as a platform for oncolytic virotherapy, vaccine vectors, and the rational design of antiviral strategies against both VSIV and other emerging rhabdoviruses.

Virion Architecture: The Bullet and Its Layers

The mature VSIV virion is a highly ordered, membrane-bound particle. Its most conspicuous feature is the bullet-shaped or conical morphology, which is a defining characteristic of the Rhabdoviridae family [4, 16]. The particle is composed of a lipid envelope derived from the host cell plasma membrane during budding, which is studded with approximately 1,200 trimeric spikes of the viral glycoprotein (G). The G protein, the primary target of neutralizing antibodies, mediates virus entry by binding to cellular receptors, primarily the low-density lipoprotein receptor (LDLR) and its family members, and facilitating pH-dependent membrane fusion. As detailed by Munis et al., the G protein undergoes a dramatic conformational rearrangement from a pre-fusion to a post-fusion state, a process that is essential for the delivery of the viral genome into the host cell cytoplasm. Monoclonal antibodies, such as IE9F9, neutralize VSIV by binding near the receptor binding site and directly competing with cellular LDLR, while cross-neutralizing antibodies like 8G5F11 bind to a region that inhibits this critical conformational change, highlighting the vulnerability of this molecular machine to immune pressure [14].

Beneath the envelope lies the matrix protein (M), a multifunctional protein that serves as the essential bridge between the viral envelope and the helical ribonucleocapsid core [1]. The M protein is a key driver of viral assembly and budding, orchestrating the shape of the virion and providing structural stability. In-silico analysis of the VSIV matrix protein reveals a protein heavily dominated by alpha-helical regions, and these structural elements are highly conserved, forming a consistent tertiary structure validated by rigorous quality assessment methods [1]. This structural consistency is critical; the M protein must interact simultaneously with the cytoplasmic tail of the G protein in the envelope and the nucleocapsid (N-RNA) complex in the core, effectively pinning the bullet shape. Furthermore, the M protein is a potent inhibitor of host gene expression, shutting off host cell transcription and translation to prioritize viral replication. This multifunctionality, structural and immune-evasive, makes the M protein a central player in the virus’s lifecycle and a target for antiviral intervention [1, 13].

The core of the virion is the helical ribonucleocapsid (RNP), which consists of the negative-sense genomic RNA tightly encapsidated by the nucleoprotein (N). This N-RNA complex is the template for both transcription and replication. Associated with the RNP are the viral RNA-dependent RNA polymerase (L, or large protein) and its cofactor, the phosphoprotein (P). The L protein, the catalytic engine of the virus, is responsible for all RNA synthetic activities, including transcription of subgenomic mRNAs and replication of the full-length genome. The P protein is an essential cofactor that delivers the L polymerase to the N-RNA template. Together, the N, P, and L proteins form the minimal replication and transcription unit, and the high degree of conservation in the P and L genes, as identified through phylogenomic analyses of epidemic lineages, likely reflects the strong functional constraints on these components [2]. The structural organization of these proteins within the virion is not random; rather, it forms a tightly coiled helix that gives the particle its characteristic shape and protects the RNA genome from nucleases and host innate immune sensors [1, 4, 16].

Genome Organization: A Masterclass in Transcriptional Economy

The VSIV genome is a non-segmented, single-stranded, negative-sense RNA molecule of approximately 11,161 nucleotides [27, 28]. The genome organization is remarkably simple yet highly efficient: it contains only five structural genes, arranged in a strict linear order from the 3′ to the 5′ end: 3′-leader-N-P-M-G-L-trailer-5′ [5, 15, 23]. This gene order is not arbitrary; it has profound implications for viral gene expression. The viral polymerase enters the genome at the 3′ end, at the leader region, and transcribes the genes sequentially. At each gene junction, the polymerase encounters a conserved set of cis-acting signals that instruct it to stop transcription of the upstream gene, polyadenylate the mRNA, and then restart transcription at the next gene. This stop-start mechanism is inherently inefficient, meaning that the polymerase progressively falls off the template as it moves down the genome. This results in a steep transcriptional gradient, where the most 3′-proximal gene (N) is transcribed in the greatest abundance, and the most 5′-distal gene (L) is transcribed at the lowest level. This gradient is essential for the proper stoichiometry of viral proteins: the N protein, required in vast quantities to encapsidate progeny genomes, is produced in abundance, while the L polymerase, needed only in catalytic amounts, is produced in very small quantities [5].

The leader region (approximately 47 nucleotides) and the trailer region at the 5′ end are non-coding but contain critical signals for genome replication and encapsidation. The leader region serves as the primary promoter for both transcription by the viral polymerase and for the initiation of replication, where the polymerase reads through the gene-junction signals to produce a full-length complementary positive-sense antigenome [5]. The intergenic regions between the genes also contain highly conserved sequences. These dinucleotide sequences (typically GA) are crucial for the termination and re-initiation of transcription. Critically, alterations in these intergenic regions can affect viral fitness and pathogenesis. For instance, a comparative genome analysis of two epidemic strains of VSIV, IN98COE (from the 1997–1998 outbreak) and IN0919WYB2 (from the 2019–2020 outbreak), identified a 14-nucleotide insertion in the G-L intergenic region of the more recent strain [27]. This non-coding insertion was associated with significant phenotypic differences, including higher virulence and enhanced contact transmission in a porcine model, suggesting that even subtle changes in genome organization can have profound biological consequences [2, 27].

The genetic plasticity of the VSIV genome is also evident in the presence of single nucleotide polymorphisms (SNPs) that differentiate viral subpopulations during epidemics. Phylogenomic analyses of the 2019–2020 US epidemic lineage, which was traced back to its ancestral origin in Chiapas, Mexico, revealed that the viral population diversified into at least four subpopulations [2]. Intriguingly, the majority of these SNPs were synonymous mutations, changes in the nucleotide sequence that do not alter the amino acid sequence of the encoded protein, indicating that purifying selection was the dominant evolutionary force, preserving the epidemic phenotype. However, specific codon sites under positive selection were identified in the P, M, G, and L proteins, suggesting that adaptive evolution at the amino acid level also plays a role in the virus’s ability to establish a foothold in new environments [2]. These findings underscore that the VSIV genome, while seemingly rigid in its fundamental organization, is subject to continuous evolutionary refinement, with changes in both coding and non-coding regions contributing to the virus’s emergence and spread [2, 3, 26]. The genome, therefore, is not a static blueprint but a dynamic entity, fine-tuned by selection pressures encountered during transmission cycles between insect vectors and mammalian hosts, a fact that has direct implications for diagnostic assay design and the surveillance of this economically consequential pathogen, which is a WOAH-listed disease due to its clinical similarity to foot-and-mouth disease [12, 15, 23].

Molecular Pathogenesis: Matrix Protein Structure and Role in Viral Assembly

The matrix (M) protein of Vesicular Stomatitis Indiana Virus (VSIV) is a multifunctional, 229-amino-acid polypeptide that serves as the central architectural scaffold of the virion, orchestrating the final stages of viral assembly and egress. While the glycoprotein (G) and nucleoprotein (N) have historically garnered significant attention due to their roles in receptor binding and genome encapsidation, it is the M protein that executes the critical biophysical process of bridging the viral envelope with the internal ribonucleoprotein (RNP) core. An exhaustive understanding of the M protein's molecular structure, its dynamic conformational states, and its interactions with both viral and host components is essential for deciphering VSIV pathogenesis and for the rational design of attenuated vaccine vectors and oncolytic therapeutics. This section provides a deep, mechanistic analysis of the M protein's architecture and its indispensable function in virion morphogenesis, drawing exclusively from the provided corpus of contemporary research.

Primary Sequence and Predicted Secondary Structure: An Alpha-Helical Framework

The foundation of the M protein's function lies in its primary amino acid sequence, which dictates a highly organized secondary structure. Recent in silico characterizations have provided a detailed physicochemical profile of the VSIV M protein, revealing that it is dominated by alpha-helical regions, a feature that is critical for its structural integrity and its ability to form stable protein-protein interfaces [1]. These predictive models, validated through rigorous quality assessment methods, indicate a consistent and robust tertiary structure, suggesting that the M protein is not a disordered polypeptide but rather a compact, globular entity. The preponderance of alpha helices is a common theme among rhabdoviral matrix proteins, as these motifs provide the rigidity necessary to form a stable protein lattice on the inner leaflet of the viral membrane. The in silico approach further confirmed that the protein's domains are structured to facilitate its dual role: binding to the cytoplasmic tail of the G protein on one side and to the nucleocapsid (N-RNA complex) on the other. This structural prediction aligns with the known functional necessity for the M protein to act as a conformational bridge, a role that would be impossible without a well-defined, stable tertiary fold [1]. The functional annotation from these analyses explicitly confirms that the protein is evolutionarily optimized for its role in forming the virus particle, acting as the central organizer of the virion architecture [1].

Beyond static structure, the M protein must exhibit a degree of conformational plasticity to orchestrate the dynamic process of budding. Molecular dynamics simulations, as applied in recent studies, have begun to model the behavior of the M protein under various physiological conditions, showing how its atoms and molecular groups interact to enable assembly [1]. These simulations are crucial for understanding how the M protein transitions from a soluble, cytoplasmic form to a membrane-associated polymerized form. The energy landscape of the M protein likely allows it to undergo subtle conformational shifts that expose critical binding interfaces for the RNP complex and the G protein only when the protein is concentrated at the plasma membrane, thereby ensuring that assembly is spatially and temporally controlled. Without these dynamic properties, the assembly process would be inefficient and prone to errors, directly impacting viral fitness and pathogenicity.

Functional Domains and the Orchestration of Budding

The M protein's role in viral assembly is not merely passive scaffolding; it is an active driver of the budding process. The protein contains several discrete functional domains that mediate its interactions. The N-terminal domain is primarily responsible for the association with the plasma membrane and the self-association of M proteins into a tightly packed paracrystalline array. This multimerization is the driving force behind the deformation of the host cell membrane, initiating the process of envelopment. The central and C-terminal domains contain the binding sites for the RNP core. The interaction between M and the RNP is a high-affinity event that condenses the helical nucleocapsid into a tightly coiled "skeleton" structure, enabling its efficient packaging into the progeny virion. Disruption of this domain through mutagenesis leads to a severe defect in the incorporation of the RNP into budding particles, resulting in the release of non-infectious "envelope-only" particles. This underscores the absolute requirement for the M-RNP interaction in the production of a competent virion.

The C-terminal region of the M protein also harbors the binding site for the cytoplasmic tail of the G protein (G-tail). This interaction links the external glycoprotein spikes to the internal matrix layer, ensuring that the envelope is specifically acquired around the RNP-M core. This is a critical checkpoint for quality control; only virions that have properly incorporated the G protein will be competent for subsequent entry into a new host cell. The specificity of this interaction has been exploited in the development of recombinant VSV-based vaccines, such as the rVSVΔG-ZEBOV-GP vaccine for Ebola virus disease. In this platform, the VSIV G gene is replaced with the Zaire ebolavirus glycoprotein (GP) gene, meaning the M protein must now interact with a heterologous G-tail [13, 22]. The success of this platform demonstrates the remarkable plasticity of the M protein's binding pocket, but also highlights that subtle differences in the G-tail sequence can affect assembly efficiency and vector immunogenicity [13]. This is a key consideration for the World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO), as VSV-vectored vaccines represent a critical tool for controlling transboundary animal diseases and emerging zoonoses (e.g., Ebola, Zika), and the molecular efficiency of their assembly dictates both vaccine yield and potency.

Evolutionary Constraints and Adaptive Mutations in the Matrix Gene

The M protein, while structurally robust, is not genetically static. Phylogenomic analyses of epidemic VSIV lineages circulating in the United States between 2019 and 2020 have revealed that the M gene is under significant selective pressure. Studies have identified specific single nucleotide polymorphisms (SNPs) that differentiate subpopulations of the virus, with some of these non-synonymous mutations falling within the M gene [2, 23, 27]. These mutations can have profound effects on viral pathogenesis. For instance, a comparative genomic analysis of two epidemic strains, the 1998 isolate IN98COE and the 2019–2020 isolate IN0919WYB2, documented 121 distinct mutations across the genome, including a 14-nucleotide insertion in the G-L intergenic region and multiple substitutions within the M open reading frame [27]. When tested in an in vivo porcine model, the IN0919WYB2 strain, despite having specific M protein mutations, demonstrated a slightly higher virulence and greater transmissibility by contact than the older strain, although the newer strain paradoxically showed lower overall viral RNA loads in clinical samples [27]. This suggests that mutations in the M protein can alter the "quality" of the infectious particle (e.g., specific infectivity or stability) rather than simply the quantity of progeny. It is plausible that adaptive changes in the M protein fine-tune the efficiency of assembly or the stability of the virion in the environment, thereby affecting transmission dynamics.

The evolutionary analysis of epidemic lineages also highlights the importance of purifying selection in maintaining the functional integrity of the M protein [2]. However, specific codon sites within the M gene have been identified as being under positive selection, suggesting that these residues are adaptive hotspots that allow the virus to respond to changing ecological or immunological pressures [2]. The ability of the M protein to tolerate these mutations without losing its core function is a testament to its robust structural design. This genetic flexibility is a key factor in the emergence of new epidemic lineages, as observed with the 2019–2020 VSIV outbreak, which was the largest in 40 years [23]. The U.S. Centers for Disease Control and Prevention (CDC) and the United States Department of Agriculture (USDA) have noted that these outbreaks are characterized by incursion from endemic zones in Mexico, followed by overwintering and expansion; the molecular adaptations in the M protein likely contribute to the virus's ability to establish these new foci [11, 15, 23, 24].

Host Antagonism and the Interplay with TRIM69

The M protein's pathogenic role extends beyond assembly into active antagonism of the host antiviral response. A critical cellular restriction factor for VSIV is the interferon-stimulated gene (ISG) product TRIM69, an E3 ubiquitin ligase that potently and specifically inhibits VSIV replication [4]. Remarkably, the specificity of this restriction is so high that a single amino acid substitution in the VSIV genome can govern the virus's sensitivity or resistance to TRIM69 [4]. While the exact target of TRIM69 is still under investigation, it is highly plausible that the M protein is a prime candidate. The M protein is the most abundant protein in the virion and is a known target for post-translational modifications. It is conceivable that TRIM69 recognizes a conserved structural motif on the M protein, tagging it for ubiquitination and subsequent proteasomal degradation, thereby halting assembly before it begins. The discovery that TRIM69 is itself under positive selection in human populations suggests an ancient arms race between the host and vesiculoviruses, with the M protein serving as a key battleground [4]. The ability of VSIV to escape TRIM69-mediated restriction through a single point mutation in its genome (likely in the M protein) underscores the intense selective pressure at this interface. This interplay is directly relevant to the safety and efficacy of VSIV-based oncolytic and vaccine vectors (e.g., VSV-IFNβ-NIS for multiple myeloma), as the presence of functional TRIM69 in human tissues could limit the spread of the therapeutic virus, while mutations that allow escape could inadvertently increase pathogenicity [4, 20, 22].

Integration with the Viral Envelope and Lipid Rafts

The final stage of assembly involves the M protein directing the budding process to specific microdomains of the plasma membrane, known as lipid rafts. The M protein's affinity for cholesterol- and sphingolipid-rich domains facilitates the concentration of both the RNP and the G protein at these sites. This co-localization is essential for efficient pinching off of the nascent virion. The M protein also interacts with components of the host ESCRT (Endosomal Sorting Complexes Required for Transport) machinery, co-opting the cell's own vesicle scission apparatus to mediate the final membrane fission event that releases the mature virion. The M protein contains motifs (e.g., PPxY and PSAP) that recruit ESCRT-associated proteins like Tsg101 and Nedd4, hijacking the cellular pathway normally used for multivesicular body formation. This is a point of vulnerability; targeting the M protein's interaction with ESCRT components is a potential avenue for antiviral therapy. The sensitivity of the M protein's assembly function to genetic change is also evident in the evolution of the virus. Studies on the 2020 outbreak in Kansas demonstrated that the virus could be detected in various insect vectors, including Culicoides midges and Simulium black flies, and that viral RNA could be found in nulliparous individuals, suggesting transovarial transmission [11]. This implies that the M protein must be stable enough to survive the environmental and physiological challenges of an arthropod vector, adding another layer of selective constraint on its sequence.

In summary, the VSIV M protein is a molecular marvel of structural biology and evolutionary adaptation. Its alpha-helical framework, dynamic conformational states, and finely tuned binding interfaces allow it to function as the central conductor of viral assembly, bridging the internal RNP core with the external glycoprotein envelope. The M protein is also a key determinant of host range and pathogenesis, serving as both a target for host restriction factors like TRIM69 and a critical locus for adaptive evolution during epidemic spread. Understanding the atomic details of the M protein's structure and its interaction network is not merely an academic exercise; it is foundational for the veterinary and medical applications of VSIV, from the development of improved oncolytic viruses and vaccine vectors to the surveillance of economically devastating livestock diseases as defined by WOAH.

Phylogenomic Signatures and Evolutionary Drivers of Epidemic VSIV Lineages

The emergence of epidemic vesicular stomatitis Indiana virus (VSIV) lineages beyond its endemic range represents a critical juncture in the evolutionary trajectory of this rhabdovirus. The 2019–2020 epidemic in the United States, the largest VSIV epizootic in over four decades, provided an unprecedented opportunity to dissect the genomic hallmarks and selective forces that govern the transition from endemic enzootic circulation to expansive epidemic spread [23]. This episode, involving 1,144 confirmed premises across eight states in 2019, followed by a secondary expansion in 2020, marked the first widespread circulation of the Indiana serotype since the 1997–1998 outbreak [23, 27]. A comprehensive phylogenomic framework, built upon 87 full-length VSIV genomes from this epidemic, revealed that the ancestral lineage of the 2019–2020 clade can be traced with high confidence to a specific group of isolates circulating in the endemic zone of Chiapas, Mexico [2]. This phylogenetic anchoring substantiates the long-held hypothesis that the southern Mexican endemic focus serves as the ultimate source for epizootic incursions into the United States [8, 15].

Phylodynamic Structure and Subpopulation Differentiation

The epidemic lineage did not maintain a homogeneous genetic structure during its northward expansion. Instead, it underwent a rapid process of diversification, resolving into at least four distinct subpopulations during its circulation within the United States [2]. This differentiation was characterized by a pronounced preponderance of synonymous single nucleotide polymorphisms (SNPs) delineating these subpopulations, indicating that much of the early genetic divergence was shaped by neutral processes and genetic drift rather than immediate adaptive pressure [2]. However, this neutral backdrop belies the intense selective scrutiny imposed by the host environment. Purifying selection emerged as the dominant evolutionary force, acting robustly to conserve the epidemic phenotype. This selective regime preferentially targeted the phosphoprotein (P) and glycoprotein (G) genes, which were identified as the principal drivers of lineage evolution [2]. The P protein’s central role in viral RNA transcription and replication, and the G protein’s function in receptor binding and membrane fusion, render them primary targets for host immune surveillance and intrinsic antiviral factors.

Signatures of Positive Selection and Functional Correlates

Despite the overall prevalence of purifying selection, the phylogenomic analysis identified discrete codon sites under positive selection distributed across the P, matrix (M), G, and large polymerase (L) proteins [2]. The localization of these positively selected sites is not random; they map to specific functional domains critical for viral biology. For instance, sites under positive selection within the G protein may influence antigenic variation and the ability to evade neutralizing antibodies, which are known to target epitopes near the receptor-binding site and the fusion domain [14]. Similarly, positive selection within the M protein, a key structural component that orchestrates viral budding and suppresses host gene expression [1], may affect interactions with cellular proteins that restrict viral assembly. The functional impact of these mutations is underscored by ancestral state reconstruction analyses, which demonstrated that the emergence of these positively selected codons was temporally correlated with the adaptation of the epidemic lineage at the population level [2].

A compelling line of evidence linking genotype to phenotype emerged from the comparative genomics of two major epidemic strains: IN98COE (representative of the 1997–1998 lineage) and IN0919WYB2 (representative of the 2019–2020 lineage). Genomic alignment revealed 121 distinct mutations between these strains, including a notable 14-nucleotide insertion in the intergenic region between the G and L genes of IN0919WYB2 [27]. This insertion, located within the critical transcriptional termination-polyadenylation signals, has the potential to alter the gradient of gene expression downstream, a key regulatory mechanism for rhabdoviruses. The phenotypic consequences were demonstrable in an in-vivo pig model: although the 1998 lineage produced higher and more prolonged viral RNA titers, the 2019 lineage (IN0919WYB2) exhibited slightly greater virulence, more efficient contact transmission, and a markedly higher propensity to generate intra-host variability during a single infection–contact transmission cycle [27]. This capacity for rapid de novo diversification within a single host provides a mechanistic basis for the successful establishment of multiple subpopulations in the field.

Phylogeographic Drivers and Vector-Mediated Expansion

The interplay between viral genomics and geography during the 2019–2020 epidemic further illuminates the evolutionary drivers of VSIV. A positive correlation between genetic and geographical distances was established for a representative panel of viruses collected in Colorado, suggesting that spatial isolation and local adaptation to distinct ecological niches contributed to the differentiation of the subpopulations [2]. This spatial-genetic structure is likely reinforced by the biology of the arthropod vectors responsible for transmission. During the 2020 outbreak in Kansas, insect surveillance identified VSIV RNA in Culicoides sonorensis, C. stellifer, C. variipennis, and Simulium meridionale, with the detection of virus in nulliparous individuals suggesting potential transovarial or venereal transmission mechanisms [11]. Similarly, black fly surveillance along the Rio Grande demonstrated that VSIV RNA could be detected in vectors at sites not directly co-located with infected livestock, expanding the known spatial dynamics of virus circulation [24]. The correlation of vector abundance with lagged precipitation and vegetation indices underscores the role of environmental variables in modulating transmission intensity [24].

The Role of Host Restriction Factors as Evolutionary Sculptors

An often-overlooked driver of VSIV evolution is the selective pressure imposed by host antiviral proteins. The identification of tripartite motif-containing protein 69 (TRIM69) as a potent, IFN-induced inhibitor of VSIV reveals a critical host-imposed bottleneck [4]. Remarkably, TRIM69 exhibits specificity for VSIV that is so acute that a single amino acid substitution in the viral genome can confer resistance or sensitivity. Furthermore, the TRIM69 gene in human populations bears signatures of positive selection, indicating an ancient and ongoing arms race between the host and vesiculoviruses [4]. This molecular antagonism likely constrains the mutational landscape of the viral G protein and other targets, channeling VSIV evolution toward residues that evade TRIM69 restriction while preserving essential entry functions. The convergence of positive selection signals in the G protein from both population-level phylogenomics [2] and host restriction factor interactions [4] highlights the multifaceted selective environment that shapes epidemic VSIV lineages.

Diagnostic and Surveillance Implications of Genomic Variability

The genetic heterogeneity observed within and between epidemic lineages has direct consequences for molecular diagnostics. The large genetic variability of VSV poses significant challenges for targeted assays; indeed, an earlier multiplex real-time RT-PCR assay failed to detect certain VSNJV lineages from Mexico, prompting a critical redesign of probe and primer sets to encompass the full breadth of circulating genetic diversity [25]. This experience is a cautionary tale for VSIV surveillance: the rapid evolution of epidemic lineages, including the accumulation of SNPs and the emergence of novel genotypes, requires continuous validation and updating of diagnostic frameworks. The genomic data generated from the 2019–2020 outbreak have already enabled the refinement of phylogenetic baselines for early detection of epidemic precursors emerging from Mexico [2]. Establishing a phylogenomic early warning system, as advocated by veterinary authorities and informed by bodies such as the World Organisation for Animal Health (WOAH), will necessitate sustained sequencing efforts in both the endemic zone (southern Mexico and Central America) and the epizootic front (the western United States) [8, 26]. The near-full-length genomes now available from endemic Mexican strains and historical isolates provide essential reference points for tracking the emergence of future high-impact lineages [26, 29, 30], while contemporaneous sequences from laboratory-adapted strains offer a control for understanding attenuation and gain-of-function mutations [28]. Together, these datasets form the foundation for predicting the evolutionary trajectory of VSIV and mitigating the economic impact of future incursions [12].

Epidemiology: Transmission Dynamics and Geographic Spread (2019–2020 US Epidemic)

The 2019–2020 Vesicular Stomatitis Indiana Virus Epidemic: A Contextual Framework

The 2019–2020 epizootic of vesicular stomatitis Indiana virus (VSIV) represents a landmark event in the history of vesicular stomatitis (VS) in the United States, being the largest and most geographically expansive outbreak of the Indiana serotype in four decades. Prior to 2019, VSIV had not been isolated as the causative agent of a major US epidemic since 1998, with the intervening years dominated by the New Jersey serotype (VSNJV) [23]. The sudden re-emergence of VSIV as the predominant serotype, its extensive spread across previously unaffected regions, and its sustained circulation over two consecutive transmission seasons, fundamentally altered the epidemiological landscape of VS in North America. This section dissects the intricate transmission dynamics, vector ecology, and genomic evolution that underpinned this unprecedented event, drawing upon integrated analyses of field surveillance, molecular phylogenetics, and experimental pathogenesis.

Geographic Spread and Premises Affected: The 2019 Incursion and 2020 Expansion

The 2019 VSIV incursion began in June and persisted through December, ultimately affecting 1,144 premises across 111 counties in eight states: Colorado, Kansas, Nebraska, New Mexico, Oklahoma, Texas, Utah, and Wyoming [23]. This focal area, centered on the Rocky Mountain and southwestern plains, is the traditional arena for VS outbreaks in the US, but the sheer scale was exceptional. For the first time in decades, VSIV extended eastward into Kansas and Missouri, a geographic expansion that challenged the conventional belief that the Indiana serotype was confined to the western states [11, 23]. In 2020, a second wave materialized from April to October, involving 326 premises across 70 counties in eight states: Arizona, Arkansas, Kansas, Missouri, Nebraska, New Mexico, Oklahoma, and Texas [23]. Notably, while the dominant serotype remained VSIV, a separate incursion of VSNJV occurred in south Texas, highlighting the simultaneous circulation of both serotypes within the same epidemic period [23].

The geographic progression of the 2020 outbreak was documented through intensive vector surveillance along the Rio Grande in southern New Mexico. The index case of VSIV in 2020 was identified at a central point of a longitudinal study on black fly (Simulium spp.) populations, providing a serendipitous opportunity to correlate vector dynamics with disease onset [24]. Black fly emergence was triggered by the release of Rio Grande water from an upstream dam in March 2020, and their abundance was significantly associated with two-month and one-year lagged precipitation, maximum temperature, and vegetation greenness (NDVI) [24]. This abiotic coupling suggests that climatic drivers, particularly water availability and temperature, are critical determinants of vector population pulses and, consequently, the timing and intensity of VSIV transmission.

Transmission Dynamics: Vector Involvement and the Role of Biting Flies

VSIV is typified as a vector-borne pathogen, and the 2019–2020 epidemic provided definitive evidence for the involvement of multiple dipteran taxa in its dissemination. Entomological investigations during the 2020 outbreak in Kansas recovered VSIV RNA from field-collected Culicoides sonorensis, Culicoides stellifer, Culicoides variipennis, and Simulium meridionale [11]. The detection of virus in nulliparous individuals of C. sonorensis and C. variipennis, females that have not yet taken a blood meal, suggests the possibility of transovarial or venereal transmission, which could serve as a mechanism for virus maintenance across seasons [11]. This is the first report of VSIV in C. stellifer and the first report of either serotype in S. meridionale collected near outbreak premises [11]. These findings expand the known vector spectrum and underscore the ecological plasticity of VSIV.

Along the Rio Grande, VSIV RNA was detected in 11 pools comprising five black fly species, with five pools yielding near-full-length or partial viral sequences [24]. Critically, these black flies were collected not on premises with infected domestic animals but from sylvatic sites, implying that VSIV can circulate in wild vector populations independent of livestock cases [24]. This off-premise detection is a significant departure from previous assumptions and points to a more complex transmission cycle involving wildlife or environmental reservoirs. Indeed, a serosurvey of feral swine in the western US between 2013 and 2021 found neutralizing antibodies against VSIV in a single animal from Kinney County, Texas, sampled in December 2019, a finding temporally and spatially aligned with a confirmed VSIV outbreak in horses in the same county in June 2019 [9]. Although the very low seroprevalence (0.02%) suggests feral swine are not an endemic reservoir, they may serve as sporadic sentinels or incidental hosts.

In contrast, transmission dynamics within the endemic range of VSIV in Chiapas, Mexico, reveal a different pattern. A two-year longitudinal study at five cattle ranches detected VSNJV RNA in all four potential vector taxa (blackflies, sandflies, biting midges, and mosquitoes) at a rate of 11% of 874 pools, whereas VSIV RNA was found only in four pools of mosquitoes [8]. The dominance of VSNJV in the endemic zone, with a seroprevalence in adult cattle of 75–100% for VSNJV versus only 0.6% for VSIV, suggests that VSIV may exist in a cryptic or low-level cycle in southern Mexico, periodically spilling over into epidemic lineages [8]. This fits with phylogenetic evidence that the 2019–2020 US epidemic lineage originated from a group of isolates circulating in Chiapas, Mexico [2].

Genomic Epidemiology and Phylogenomics: Diversification and Selection

Phylogenomic analysis of 87 full-length VSIV genome sequences from the 2019–2020 US epidemic has provided unprecedented insight into the evolutionary forces shaping this outbreak. For the first time, Zárate et al. (2024) described the phylogenomic signatures of an epidemic VSIV lineage, demonstrating that the lineage diversified into at least four distinct subpopulations during its circulation in the US [2]. These subpopulations were differentiated by specific single nucleotide polymorphisms (SNPs), with a notable preponderance of synonymous mutations, indicating that purifying selection, rather than diversifying selection, was the dominant force maintaining the epidemic phenotype [2]. The P and G genes were identified as the principal drivers of lineage evolution, with multiple codon sites under positive selection detected in the P, M, G, and L proteins [2].

Ancestral state reconstruction traced the origin of the epidemic lineage to a specific group of isolates from Chiapas, Mexico, reinforcing the concept of the endemic-epidemic continuum [2]. Importantly, a positive correlation between genetic and geographical distances was established for a representative set of viruses from Colorado, suggesting that positive selection at specific codon positions may have facilitated the adaptation of different subpopulations to distinct local environments [2]. This form of local adaptation could explain the rapid geographic expansion and persistent transmission across diverse ecoregions.

The low genetic diversity observed during the 2019 outbreak in Colorado, as reported by Bertram et al. (2023), is consistent with a recent founder effect and rapid spread [3]. Near-full-length genome sequences from Wyoming and Colorado in 2019 revealed a relatively homogeneous viral population, which is typical of a single incursion event [6]. However, by 2020, greater nucleotide variability was apparent, particularly in isolates from Kansas, where a 14-nucleotide insertion in the intergenic region between the G and L genes was identified in the IN0919WYB2 strain [27, 32]. This insertion distinguishes the 2019–2020 lineage from the IN98COE strain responsible for the 1998 outbreak and may contribute to the observed phenotypic differences.

Overwintering and Recurrence: The Role of Refugia

A key epidemiological feature of VS in the US is the phenomenon of overwintering: the virus persists through the cold months to spark a second wave of transmission the following spring. The 2019–2020 epidemic provides compelling evidence for overwintering. After the initial 2019 incursion, a subsequent expansion occurred in 2020 in states that had been affected in 2019 (e.g., Kansas, Oklahoma, Texas) as well as new areas (Arizona, Arkansas, Missouri) [23]. Phylogenetic analysis supported the hypothesis that the virus overwintered within the US rather than being reintroduced from Mexico each year [12, 23].

The mechanisms of overwintering remain debated. Possible explanations include vertical transmission in vectors (as suggested by the detection of VSIV in nulliparous Culicoides [11]), persistent infection in vertebrate reservoir hosts (e.g., rodents or insectivores), or survival in hibernating adult flies. The detection of VSIV RNA in black flies collected off-premise during the winter months would be a critical piece of evidence but has not yet been reported. Nevertheless, the genetic continuity between the 2019 and 2020 isolates strongly argues against independent introductions from Mexico and underscores the need for enhanced winter surveillance.

Experimental Evidence for Phenotypic Variation in Epidemic Strains

The 2019–2020 epidemic lineage (represented by the IN0919WYB2 strain) was compared to the 1998 epidemic strain (IN98COE) in a pig model. Hole et al. (2024) demonstrated that IN0919WYB2, despite producing lower viral RNA loads in clinical samples, was slightly more virulent (as assessed by clinical lesion scores) and significantly more efficient at establishing infection through contact transmission [27]. Furthermore, infectious virus was recovered from a greater number of samples, and the IN0919WYB2 strain generated more sequence variability during a single infection–contact transmission event, indicating a higher evolutionary potential [27]. These phenotypic differences, enhanced transmissibility and capacity for rapid genetic diversification, likely contributed to the unprecedented scale of the 2019–2020 epidemic.

In contrast, earlier experimental studies using Central American isolates found that bovine-derived VSIV strains from that region were more virulent in pigs than a US equine isolate, suggesting that the endemic viruses may possess a fitness advantage when introduced into naive livestock populations [31]. This aligns with the hypothesis that the 2019–2020 lineage, having evolved in the Chiapas endemic zone, was pre-adapted for explosive transmission in the US.

Implications for One Health Surveillance and International Coordination

The 2019–2020 VSIV epidemic underscores the intrinsic link between endemic transmission in southern Mexico and epizootic emergence in the US. The World Organisation for Animal Health (WOAH) and the US Department of Agriculture (USDA) recognize VS as a reportable disease due to its clinical similarity to foot-and-mouth disease and its economic impact on livestock trade [12, 15]. The genetic signatures identified in the epidemic lineage could serve as the basis for an early warning system, enabling the detection of epidemic precursors in Mexico before they cross the border [2]. Already, enhanced molecular diagnostic assays, such as the redesigned multiplex real-time RT-PCR developed by Hole et al. (2021), have increased the capacity to detect VSIV lineages of Central American origin, thereby strengthening surveillance capacity [25].

The involvement of multiple vector species, the detection of virus in off-premise collections, and the evidence for overwintering collectively indicate that VSIV transmission is far more complex than a simple livestock–vector cycle. Future control strategies must integrate vector management (e.g., targeted insecticide application during peak abundance), movement restrictions on livestock with lesions, and real-time genomic surveillance of both vectors and domestic animals. The 2019–2020 epidemic serves as a stark reminder that the interplay between climate, vectors, and viral evolution can rapidly reshape the epidemiological landscape of an ancient livestock disease.

Diagnostic and Surveillance Approaches for VSIV Detection and Strain Differentiation

The accurate and rapid detection of Vesicular Stomatitis Indiana Virus (VSIV), coupled with the ability to differentiate its circulating strains, forms the cornerstone of effective outbreak management and the development of robust early warning systems. The clinical presentation of vesicular stomatitis (VS) in livestock, vesicular lesions on the muzzle, oral mucosa, coronary bands, and teats, is pathognomonic only in its resemblance to far more economically devastating transboundary diseases, chief among them Foot-and-Mouth Disease (FMD). This clinical mimicry compels animal health authorities, including those under the mandates of the World Organisation for Animal Health (WOAH) and national bodies like the United States Department of Agriculture (USDA) and the Canadian Food Inspection Agency (CFIA), to implement immediate diagnostic interventions upon suspicion of vesicular disease. The diagnostic and surveillance framework for VSIV has therefore evolved from classical virological methods into a sophisticated, multi-layered paradigm that integrates real-time molecular detection, high-throughput genomic sequencing, serological surveillance across multiple host species, and targeted entomological monitoring. This section provides an exhaustive examination of these methodologies, emphasizing their mechanistic underpinnings, operational applications, and critical role in discerning the evolutionary dynamics and transmission ecology of VSIV.

Molecular Detection: The Primacy and Pitfalls of Reverse Transcription Quantitative PCR (RT-qPCR)

The frontline diagnostic tool for VSIV during outbreaks has become real-time reverse transcription polymerase chain reaction (RT-qPCR), owing to its high sensitivity, rapid turnaround time, and ability to differentiate VSIV from other vesicular viruses, including Vesicular Stomatitis New Jersey Virus (VSNJV) and FMD virus. The standard approach targets conserved regions of the viral genome, often the nucleoprotein (N) or polymerase (L) genes, which are transcribed at high levels during infection. The development of a multiplex real-time RT-PCR (mRRT-PCR) assay that simultaneously detects and differentiates VSIV and VSNJV has been a critical advancement for regulatory laboratories [25]. This assay allows for the direct identification of the serotype involved in an outbreak from clinical samples such as vesicular fluid, epithelial tissue swabs, or lesion scrapings.

However, the utility of any molecular assay is contingent upon its primers and probes maintaining sequence complementarity with circulating viral variants. The extensive genetic diversity of VSV, particularly within its endemic range in Mexico and Central America, poses a significant challenge. A landmark study by Hole et al. (2021) [25] demonstrated this vulnerability directly. An established mRRT-PCR assay, while effective against US outbreak strains, was found to have markedly reduced sensitivity for VSNJV isolates belonging to specific genetic lineages (e.g., lineage 2.1) circulating in Mexico, failing to detect nearly 26% of samples from that region. This failure was attributed to nucleotide mismatches in the primer/probe binding regions, a consequence of the high mutation rate inherent to RNA viruses and the purifying and diversifying selection pressures acting on different lineages [2, 25]. The subsequent redesign of the assay, incorporating degenerate bases and modified probe chemistries, restored detection sensitivity to 100% for these previously undetectable lineages, while maintaining its established sensitivity for VSIV [25]. This iterative process underscores a cardinal rule in VSIV diagnostics: assays must be continuously re-evaluated and updated against a comprehensive genomic database that reflects the true genetic breadth of the virus across its entire geographic range. The genetic plasticity of VSIV, as evidenced by the identification of specific single nucleotide polymorphisms (SNPs) differentiating epidemic subpopulations during the 2019-2020 US outbreak, further reinforces the need for molecular assays that can tolerate sequence drift without sacrificing analytical sensitivity [2, 6, 32].

For routine surveillance of archived or low-quality samples, conventional RT-PCR followed by amplicon sequencing is still employed, but the field has shifted overwhelmingly toward real-time and digital PCR platforms. The generation of near-full-length and complete genome sequences from clinical samples, now standard practice with next-generation sequencing (NGS) platforms like Illumina and Oxford Nanopore, has revolutionized our ability to not just detect VSIV, but to characterize its origin, trace its transmission pathways, and identify genetic markers of virulence or transmissibility [2, 3, 6, 26, 27, 32]. Sequence data from outbreaks, such as the 2019-2020 US epizootic, have been instrumental in supporting molecular diagnostic efforts by providing a framework of the expected genetic diversity within a given epidemic wave [6, 32].

Serological Surveillance: Bridging Historical Exposure and Active Circulation

While molecular detection confirms active infection, serological assays provide a longitudinal perspective on viral circulation, exposure history, and herd immunity. The gold standard for serological detection of VSIV remains the virus neutralization test (VN or SN). In this assay, serial dilutions of heat-inactivated serum are incubated with a standardized dose of infectious VSIV (typically the Indiana serotype), and the mixture is then applied to a susceptible cell monolayer (e.g., Vero or BHK-21 cells). The highest dilution that completely inhibits the cytopathic effect (CPE) defines the neutralizing antibody titer. This assay is highly specific and can differentiate between serotypes, but it is labor-intensive, requires live virus and cell culture facilities (biosafety level 2), and takes several days to complete. Despite these drawbacks, VN remains the confirmatory test of choice for WOAH reporting and for studies requiring precise serotype-specific data [9, 19, 21].

The utility of VN is exemplified in epidemiological surveys across the Americas. A large-scale study of feral swine (Sus scrofa) in the western US between 2013-2021 tested 4,541 samples using VN. Only eight sera exhibited neutralizing activity, and just a single sample from Texas confirmed positive for VSIV by a competitive ELISA (cELISA) [9]. This low prevalence was a critical finding, suggesting that feral swine, while capable of being infected, do not serve as an endemic reservoir for VSIV in the US, contrasting with their potential role for VSNJV [9]. Similarly, VN surveys of horses in Brazil revealed high seroprevalence (up to 87.3%) against the VSIV-3 subtype in northeastern states, indicating relatively recent and widespread circulation of this specific lineage [21]. These studies demonstrate that serosurveillance of sentinel species, particularly horses which are highly susceptible, provides invaluable data on viral geography and the timing of exposure, especially in regions where clinical disease may be underreported.

Complementary to VN are enzyme-linked immunosorbent assays (ELISAs). Competitive ELISAs (cELISAs) are particularly useful for large-scale screening as they can use inactivated antigens and are less dependent on species-specific conjugates. The detection of antibodies against the VSIV glycoprotein (G) or nucleoprotein (N) by ELISA allows for high-throughput testing [9, 13, 17]. The development of specific monoclonal antibodies (mAbs), such as those targeting the G protein of VSIV (8G5F11 and IE9F9), has been critical for fine-tuning these assays. IE9F9, for instance, binds near the receptor binding site and neutralizes only VSIVind.G, while 8G5F11 is cross-neutralizing against several vesiculoviruses, binding to a region involved in conformational changes during membrane fusion [14]. This level of characterization is essential for interpreting serological data, especially when considering cross-reactivity with other vesiculoviruses like Cocal or Maraba. The comparative analysis of VSIV pathogenicity in pigs also demonstrated the importance of serological monitoring, where pigs infected with more virulent Central American isolates showed distinct antibody response patterns compared to those infected with a less virulent US isolate [31].

Advanced Diagnostics: Point-of-Care Testing and Genomic Epidemiology

The need for rapid, field-deployable diagnostics is acute during VS outbreaks to facilitate immediate quarantine and regulatory action. The development of an immunochromatographic strip (ICS) test for VSIV represents a significant step towards this goal. Using a sandwich format with colloidal gold-conjugated monoclonal antibody 1A2 targeting the VSIV G protein and a second mAb (4C3) as the capture antibody, this test provides a result within minutes. Validation against RT-PCR demonstrated a relative sensitivity of 91.4% and a specificity of 98.9%, with a detection limit of approximately 1.85 × 10³ TCID₅₀/mL [33]. The stability of the strips for up to 12 months at 4°C makes them practical for use in the field or in low-resource laboratories. While less sensitive than RT-qPCR, the ICS test serves as a rapid screening tool that can be deployed at the farm level to initiate a regulatory response while confirmatory testing is performed.

The most transformative advancement in VSIV diagnostics and surveillance is the application of genomic epidemiology. The generation of full-length genome sequences from outbreak isolates has moved from a research tool to an operational necessity. During the 2019-2020 US VSIV outbreak, phylogenomic analyses of 87 genomes revealed not just that the epizootic lineage originated from the endemic zone in Chiapas, Mexico, but that it diversified into at least four distinct subpopulations with specific SNPs in the P, M, G, and L genes [2]. These SNPs, many of which were synonymous, highlighted the role of purifying selection in maintaining the epidemic phenotype, while others under positive selection were linked to potential adaptation to specific geographical settings in Colorado [2, 3]. The ability to track these specific genetic signatures in real-time allows veterinarians and epidemiologists to connect cases across states and even across years. For example, the detection of a 14-nucleotide insertion in the intergenic region between the G and L genes in the 2019-2020 lineage (IN0919WYB2) provided a distinct marker for this particularly virulent and transmissible strain, which was more efficient at contact transmission in pig models compared to a 1998 strain [27]. This type of molecular characterization directly informs risk assessments.

Vector Surveillance and Xenomonitoring

Given that VSIV is a vector-borne virus, diagnostic surveillance must extend beyond the vertebrate host to the arthropod vector. Entomological surveillance programs, particularly in the endemic region of southern Mexico and along the US-Mexico border, are critical for early warning. The detection of VSIV RNA in field-caught insects by RT-qPCR has confirmed the role of multiple vector taxa. During the 2020 Kansas outbreak, VSIV RNA was detected in Culicoides sonorensis, Culicoides stellifer, Culicoides variipennis, and Simulium meridionale [11]. The recovery of virus from nulliparous C. sonorensis and C. variipennis suggests the possibility of transovarial or venereal transmission, indicating that these insects may serve as both biological vectors and potentially as overwintering reservoirs [11]. Similarly, a longitudinal study in Chiapas, Mexico, detected VSNJV RNA in all four potential vector taxa (blackflies, sandflies, biting midges, mosquitoes), while VSIV RNA was detected only in mosquitoes, suggesting potential differences in vector competency or transmission ecology [8].

Surveillance along the Rio Grande in New Mexico detected VSIV RNA in five species of black flies (Simulium spp.), even at sites that were not on premises with confirmed infected livestock [24]. This "xenomonitoring" provides a pre-clinical signal, showing viral activity in the environment before disease appears in sentinel animals. The spatiotemporal analysis of black fly abundance in relation to environmental variables such as precipitation, temperature, and vegetation greenness (NDVI) offers a predictive model for vector population peaks and, by extension, periods of high transmission risk [24]. These integrated surveillance strategies, which combine insect trapping with molecular virology, are essential for understanding the complex transmission cycles that link the endemic foci in Mexico to the explosive epizootics in the US [8, 23, 24].

Strain Differentiation: From Serotype to Genotype

Differentiating VSIV strains is no longer limited to the classical serological distinction between the Indiana and New Jersey serotypes. The Indiana serotype itself encompasses considerable genetic diversity, historically classified into subtypes (e.g., Indiana 1, 2, 3) based on cross-neutralization assays. Modern diagnostics have largely supplanted this with phylogenetic and phylogenomic analyses. The determination of near-full-length genome sequences from endemic strains in Mexico has revealed the existence of distinct genetic lineages that are the direct progenitors of US epidemic strains [26, 29]. For example, the 2019-2020 US outbreak strain was shown to be phylogenetically linked to a specific group of isolates from Chiapas, Mexico [2, 23]. This level of resolution allows for the tracking of specific viral lineages as they move from the endemic zone northward.

Discriminating between co-circulating serotypes and genotypes is essential during outbreaks, particularly when both VSNJV and VSIV are active. The 2020 US outbreak was predominantly VSIV, but a separate incursion of VSNJV occurred in south Texas, necessitating a diagnostic capability to differentiate them [23]. The mRRT-PCR assays [25] are designed for this purpose, but genomic sequencing of isolates from insects [11] and clinical cases [27] provides the definitive evidence needed to confirm serotype and lineage. Furthermore, detailed analysis of specific genes, such as the G glycoprotein, is critical for assessing the potential for cross-protection from vaccines or natural infection. The identification of conserved and variable epitopes on the G protein through monoclonal antibody mapping [14] provides a structural basis for understanding serological cross-reactivity and designing more refined diagnostic antigens.

In summary, the diagnostic and surveillance framework for VSIV is a dynamic, multi-faceted system that must co-evolve with the virus itself. It relies on the precision of molecular assays (RT-qPCR, NGS) for acute detection and strain characterization, the breadth of serological tools (VN, ELISA) for understanding population-level exposure, and the foresight provided by entomological surveillance. The integration of these approaches, supported by continuous genomic surveillance of both vertebrate and invertebrate populations, is the only viable path toward the development of an early warning system capable of predicting and mitigating the impact of future VSIV epizootics, as has been called for by leading veterinary research groups [2, 23]. The challenge remains to maintain a global, open-access database of VSIV sequences that is comprehensive enough to inform the next generation of diagnostic assays, ensuring they remain fit for purpose against a rapidly evolving and geographically dispersed viral pathogen.

Vaccine Development and Antiviral Strategies Targeting VSIV Proteins

The interplay between the structural and non-structural proteins of Vesicular Stomatitis Indiana Virus (VSIV) forms the foundation for both prophylactic vaccine design and the development of targeted antiviral interventions. Given the virus’s status as a WOAH (World Organisation for Animal Health)-notifiable pathogen with clinical presentations indistinguishable from foot-and-mouth disease (FMD), the economic and trade ramifications of VSIV incursions are severe, driving an urgent need for effective countermeasures [12, 15, 23]. The bipartite strategy of leveraging the VSIV genome as a vector for heterologous antigens while simultaneously targeting its own proteins for direct antiviral action has yielded a sophisticated and bifurcated field of research.

The VSIV Backbone as a Platform for Heterologous Vaccine Development

The most impactful contribution of VSIV to vaccinology is its deployment as a replication-competent recombinant vector. The rationale for this is deeply rooted in the virus’s biology. By deleting the glycoprotein (G) gene and replacing it with an immunogen from a target pathogen, the resulting recombinant VSV (rVSV) becomes entirely dependent on the foreign glycoprotein for entry, a strategy that simultaneously attenuates the virus by removing its natural tropism while focusing the immune response on the target antigen. This approach has been most famously validated with the rVSVΔG-ZEBOV-GP vaccine against Zaire ebolavirus. Studies have demonstrated that this vaccine elicits robust humoral and memory B cell responses to the Ebola glycoprotein, alongside vector-directed T cell immunity against the VSIV matrix (M) protein and nucleoprotein (NP) [13]. The transient nature of the vector-directed antibody responses, IgM and IgG to VSIV M and NP appearing in only a minority of recipients, underscores a critical advantage: the vector itself generates a self-limiting immune footprint, reducing the risk of vector neutralization upon repeat administration [13]. The safety and immunogenicity of this platform were further underscored in a high-stakes emergency post-exposure vaccination scenario following a needlestick injury, where the VSVΔG-ZEBOV vaccine induced strong innate and Ebola-specific adaptive immunity without evidence of wild-type Ebola infection [22].

This heterologous vector strategy has been expanded beyond filoviruses. To circumvent the issue of anti-vector immunity from a single serotype, a dual serotype prime-boost regimen has been engineered, utilizing an attenuated rVSV Indiana serotype (rVSVInd) prime followed by an rVSV New Jersey serotype (rVSVNJ) boost, both carrying a genetically modified Zika virus envelope (E) protein gene. In Ifnar⁻/⁻ mouse models, this strategy induced robust neutralizing antibodies and T cell responses, achieving protection against lethal Zika challenge [16]. The platform’s versatility extends to human immunodeficiency virus (HIV), where a recombinant VSIV vector expressing HIV-1 Gag (VSV-Gag) was used as a boost in a human clinical trial, demonstrating acceptable tolerability despite inducing transient systemic reactogenicity [18]. The inherent plasticity of the VSIV genome also allows for the insertion of therapeutic transgenes. The oncolytic VSV-IFNβ-NIS strain, which encodes human interferon beta (IFNβ) and the sodium iodide symporter (NIS), represents a sophisticated antiviral strategy repurposed for cancer therapy. The virally encoded IFNβ acts as an immunomodulatory “safety switch,” limiting viral replication in healthy tissues while promoting anti-tumor immunity, a design that has proven safe in Phase I trials for hematological malignancies [20].

Direct Vaccination Strategies Against VSIV in Livestock

While the vector platform is dominant, direct vaccination against VSIV in its natural livestock hosts remains a critical goal. The glycoprotein (G) is the primary target for neutralizing antibodies, and its immunogenicity has been exploited through a variety of delivery systems. Recombinant human type 5 replication-defective adenoviruses (rAd) expressing the VSIV G protein (rAd-VSV-IN-G) have been constructed and evaluated in target species. These constructs successfully induced VSV-specific antibodies and neutralizing antibody titers (reaching 1:64) in goats, as well as strong lymphocyte proliferation, indicating the generation of both humoral and cell-mediated immunity [17]. This approach is particularly appealing for livestock because adenoviral vectors can be produced at scale and are stable, circumventing the cold-chain challenges associated with live-attenuated viral vaccines.

The development of rapid diagnostic tools to support vaccination campaigns or outbreak response has also targeted the G protein. Immunochromatographic strip (ICS) tests using monoclonal antibodies (MAbs) against the VSIV G protein have achieved high relative specificity (98.9%) and sensitivity (91.4%) for field detection of the virus [33]. These MAbs, specifically 8G5F11 and IE9F9, have been instrumental in understanding neutralization mechanisms. IE9F9 binds near the receptor binding site, neutralizing VSIV by competing with the host low-density lipoprotein receptor (LDLR), while 8G5F11 exhibits broad cross-neutralization across multiple vesiculovirus G proteins by inhibiting the pH-dependent conformational shift to the post-fusion state [14]. The identification of such cross-neutralizing epitopes is invaluable for pan-vesiculovirus vaccine design.

Antiviral Strategies: Host Factors and Small Molecules

The host innate immune response provides the first line of defense against VSIV, and characterizing these factors has revealed novel therapeutic targets. The tripartite motif-containing protein TRIM69 has been identified as a potent, interferon-stimulated gene (ISG) product that specifically restricts VSIV replication. Remarkably, a single amino acid substitution in the VSIV genome can govern sensitivity to TRIM69, highlighting the specific molecular arms race between the virus and this host restriction factor [4]. Understanding the precise VSIV protein targeted by TRIM69, likely the nucleoprotein or a component of the viral polymerase, could inform the design of small molecules that mimic or enhance this restrictive activity.

Beyond host genetics, chemical modulators of immunity have shown promise. The immunomodulator Glutoxim (GLT) has demonstrated significant antiviral activity against VSIV in vitro. While GLT did not show a direct virucidal effect at high concentrations, low doses (0.1–0.5 µg/ml) led to a greater than 100-fold inhibition of VSV replication in diploid fibroblast cell lines 24 hours post-infection [34]. This concentration-dependent effect suggests that precise dosing is critical for achieving an antiviral state through immune modulation rather than direct cytotoxicity. Although the mechanism was not fully elucidated, such agents provide a potential ancillary or prophylactic strategy in outbreak settings where vaccination coverage may be incomplete.

The complex transcriptomic architecture of VSIV, which generates structured and unstructured transcripts in a cell-type-dependent manner, also presents opportunities for antiviral targeting. Nanopore-based long-read sequencing has revealed that viral gene expression is highly dynamic and varies between different cell types (e.g., human glioblastoma versus primate fibroblasts) [5]. This suggests that the viral polymerase (L protein) and its cofactor (P protein) are subject to cell-specific regulatory influences that could be exploited. For instance, targeting the intergenic regions or transcription start/stop signals identified as sources of transcriptomic complexity could disrupt the finely tuned gradient of gene expression required for efficient replication.

In-Silico Approaches for Antiviral Design

The matrix (M) protein of VSIV, which orchestrates viral assembly and budding by bridging the envelope and the core, is a high-value target for rational drug design. In-silico analyses have confirmed that the M protein is dominated by alpha-helical regions within a stable tertiary structure [1]. Molecular dynamic simulations of the M protein’s behavior under various conditions can model the interaction of potential small-molecule inhibitors with critical binding pockets. Peptide toxicity analysis of M protein-derived peptides opens the door for designing competitive inhibitors that could interfere with its interaction with the host ESCRT machinery, a process essential for viral egress. These computational workflows, ranging from physicochemical property prediction to tertiary structure validation, are rapidly accelerating the identification of lead compounds that may lack the toxicity profiles of earlier-generation antivirals [1].

The evolutionary dynamics of the VSIV genome, as revealed by phylogenomic analyses of epidemic lineages (e.g., the 2019–2020 US outbreak), provide context for antiviral durability. Positive selection on codon sites within the P, M, G, and L proteins indicates that these are the pressure points for adaptation [2]. Antiviral strategies targeting the P and L proteins are particularly attractive because they are the drivers of lineage evolution and are less exposed to humoral immune pressure compared to the G protein. The identification of synonymous and non-synonymous single nucleotide polymorphisms (SNPs) that define viral subpopulations further allows for the design of pan-lineage therapeutics that must account for the genetic diversity circulating in endemic zones like Chiapas, Mexico, where VSIV RNA can be detected in mosquito pools [8].

References

[1] S R, R SV, R PS, Prabhu P. In-Silico Approaches for Molecular Characterization, Structural Function Prediction and Peptide Toxicity Analysis of the Matrix Protein of Vesicular stomatitis Indiana Virus (VSIV). BIO Web of Conferences. 2025. DOI: https://doi.org/10.1051/bioconf/202517202007

[2] Zárate S, Bertram MR, Rodgers C, Reed K, Pelzel-McCluskey A, Gómez-Romero N, et al.. Phylogenomic Signatures of a Lineage of Vesicular Stomatitis Indiana Virus Circulating During the 2019–2020 Epidemic in the United States. Viruses. 2024. DOI: https://doi.org/10.3390/v16111803

[3] Bertram MR, Rodgers C, Reed K, Velázquez-Salinas L, Pelzel-McCluskey A, Mayo C, et al.. Vesicular stomatitis Indiana virus near-full-length genome sequences reveal low genetic diversity during the 2019 outbreak in Colorado, USA. Frontiers in Veterinary Science. 2023. DOI: https://doi.org/10.3389/fvets.2023.1110483

[4] Rihn SJ, Aziz MA, Stewart DG, Hughes J, Turnbull ML, Varela M, et al.. TRIM69 Inhibits Vesicular Stomatitis Indiana Virus. Journal of Virology. 2019. DOI: https://doi.org/10.1128/JVI.00951-19

[5] Kakuk B, Kiss A, Torma G, Csabai Z, Prazsák I, Mizik M, et al.. Nanopore Assay Reveals Cell-Type-Dependent Gene Expression of Vesicular Stomatitis Indiana Virus and Differential Host Cell Response. Pathogens. 2021. DOI: https://doi.org/10.3390/pathogens10091196

[6] O'Donnell V, Pauszek S, Xu L, Moran K, Vierra D, Boston T, et al.. Genome Sequences of Vesicular Stomatitis Indiana Viruses from the 2019 Outbreak in the Southwest United States. Microbiology Resource Announcements. 2020. DOI: https://doi.org/10.1128/MRA.00894-20

[7] Isaeva A, Porozova N, Idota E, Volodina S, Lukashev A, Malogolovkin A. Comparative analysis of oncolytic potential of vesicular stomatitis virus serotypes Indiana and New Jersey in cancer cell lines. Sechenov Medical Journal. 2023. DOI: https://doi.org/10.47093/2218-7332.2023.946.14

[8] Zhou LH, Valdez F, González IL, Urbina WF, Ocaña A, Tapia C, et al.. Vesicular Stomatitis Virus Transmission Dynamics Within Its Endemic Range in Chiapas, Mexico. Viruses. 2024. DOI: https://doi.org/10.3390/v16111742

[9] Haynes E, Cleveland CA, Brown V, Pelzel-McCluskey A, Tell RM, Stallknecht D. Surveillance of Feral Swine (Sus scrofa) in the Western USA for Antibodies to Vesicular Stomatitis Virus, 2013–21. Journal of Wildlife Diseases. 2024. DOI: https://doi.org/10.7589/JWD-D-24-00049

[10] Ayub I, Herrero M, Dolz G. Historical Serological Evidence of Human Exposure to Vesicular Stomatitis Virus (New Jersey and Indiana Serotypes) in Dairy Regions of Costa Rica (1999). Vector Borne and Zoonotic Diseases. 2026. DOI: https://doi.org/10.1177/15303667261421864

[11] McGregor BL, Rozo-Lopez P, Davis TM, Drolet B. Detection of Vesicular Stomatitis Virus Indiana from Insects Collected during the 2020 Outbreak in Kansas, USA. Pathogens. 2021. DOI: https://doi.org/10.3390/pathogens10091126

[12] Pelzel-McCluskey A. Vesicular Stomatitis Virus.. The Veterinary clinics of North America. Equine practice. 2023. DOI: https://doi.org/10.1016/j.cveq.2022.11.004

[13] Raabe V, Lai L, Morales J, Xu Y, Rouphael N, Davey R, et al.. Cellular and Humoral Immunity to Ebola Zaire Glycoprotein and Viral Vector Proteins Following Immunization with Recombinant Vesicular Stomatitis Virus-Based Ebola Vaccine (rVSVΔG-ZEBOV-GP). Vaccine. 2023. DOI: https://doi.org/10.1016/j.vaccine.2023.01.059

[14] Munis AM, Tijani M, Hassall M, Mattiuzzo G, Collins M, Takeuchi Y. Characterization of Antibody Interactions with the G Protein of Vesicular Stomatitis Virus Indiana Strain and Other Vesiculovirus G Proteins. Journal of Virology. 2018. DOI: https://doi.org/10.1128/JVI.00900-18

[15] Pelzel-McCluskey A. Vesicular Stomatitis Virus.. The Veterinary clinics of North America. Food animal practice. 2022. DOI: https://doi.org/10.1079/cabicompendium.60393

[16] Choi J, Wu K, Kim GN, Saeedian N, Seon S, Park G, et al.. Induction of protective immune responses against a lethal Zika virus challenge post-vaccination with a dual serotype of recombinant vesicular stomatitis virus carrying the genetically modified Zika virus E protein gene.. Journal of General Virology. 2021. DOI: https://doi.org/10.1099/jgv.0.001588

[17] Xue X, Yu Z, Jin H, Liang L, Li J, Li X, et al.. Recombinant adenovirus expressing vesicular stomatitis virus G proteins induce both humoral and cell-mediated immune responses in mice and goats. BMC Veterinary Research. 2021. DOI: https://doi.org/10.1186/s12917-020-02740-6

[18] Elizaga M, Li SS, Kochar N, Wilson GJ, Allen M, Tieu H, et al.. Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial. PLoS ONE. 2018. DOI: https://doi.org/10.1371/journal.pone.0202753

[19] Bezerra CS, Cargnelutti J, Sauthier JT, Weiblen R, Flores E, Alves CJ, et al.. Epidemiological situation of vesicular stomatitis virus infection in cattle in the state of Paraíba, semiarid region of Brazil.. Preventive Veterinary Medicine. 2018. DOI: https://doi.org/10.1016/j.prevetmed.2018.09.027

[20] Cook JM, Peng K, Ginos B, Dueck A, Giers M, Packiriswamy N, et al.. Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). Blood. 2018. DOI: https://doi.org/10.1182/BLOOD-2020-140853

[21] Lunkes VL, Tonin AA, Machado G, Corbellini L, Diehl GN, Santos LCd, et al.. Antibodies against vesicular stomatitis virus in horses from southern, midwestern and northeastern Brazilian States. Ciencia Rural. 2016. DOI: https://doi.org/10.1590/0103-8478CR20151135

[22] Lai L, Davey R, Beck A, Xu Y, Suffredini A, Palmore T, et al.. Emergency Postexposure Vaccination With Vesicular Stomatitis Virus–Vectored Ebola Vaccine After Needlestick. Journal of the American Medical Association (JAMA). 2015. DOI: https://doi.org/10.1001/jama.2015.1995

[23] Pelzel-McCluskey A, Christensen B, Humphreys J, Bertram MR, Keener R, Ewing R, et al.. Review of Vesicular Stomatitis in the United States with Focus on 2019 and 2020 Outbreaks. Pathogens. 2021. DOI: https://doi.org/10.3390/pathogens10080993

[24] Young KI, Valdez F, Vaquera C, Campos C, Zhou LH, Vessels HK, et al.. Surveillance along the Rio Grande during the 2020 Vesicular Stomatitis Outbreak Reveals Spatio-Temporal Dynamics of and Viral RNA Detection in Black Flies. Pathogens. 2021. DOI: https://doi.org/10.3390/pathogens10101264

[25] Hole K, Nfon C, Rodriguez LL, Velázquez-Salinas L. A Multiplex Real-Time Reverse Transcription Polymerase Chain Reaction Assay With Enhanced Capacity to Detect Vesicular Stomatitis Viral Lineages of Central American Origin. Frontiers in Veterinary Science. 2021. DOI: https://doi.org/10.3389/fvets.2021.783198

[26] Hole K, Buchanan C, Lung O, Babiuk S, Nfon C, Navarro‐López R, et al.. Near-full-length vesicular stomatitis Indiana virus genome sequences representative of endemic strains circulating in Mexico. Microbiology Resource Announcements. 2025. DOI: https://doi.org/10.1128/mra.01103-24

[27] Hole K, Sroga P, Nebroski M, Handel K, Lung O, Spinard E, et al.. Phenotypic Differences Between the Epidemic Strains of Vesicular Stomatitis Virus Serotype Indiana 98COE and IN0919WYB2 Using an In-Vivo Pig (Sus scrofa) Model. Viruses. 2024. DOI: https://doi.org/10.3390/v16121915

[28] Russell TM, Santo EE, Golebiewski L, Haseley N, Ferran MC. Near-Complete Genome Sequences of Vesicular Stomatitis Virus Indiana Laboratory Strains HR and T1026R1 and Plaque Isolates 22-20 and 22-25. Microbiology Resource Announcements. 2019. DOI: https://doi.org/10.1128/MRA.00012-19

[29] Pauszek S, O'Donnell V, Faburay B. Genome sequence of a vesicular stomatitis Indiana virus isolate collected in 1988 from a naturally infected bovine in Mexico. Microbiology Resource Announcements. 2024. DOI: https://doi.org/10.1128/mra.00012-24

[30] Fowler V, King DJ, Howson E, Madi M, Pauszek S, Rodriguez LL, et al.. Genome Sequences of Nine Vesicular Stomatitis Virus Isolates from South America. Genome Announcements. 2016. DOI: https://doi.org/10.1128/genomeA.00249-16

[31] Morozov I, Davis A, Ellsworth S, Trujillo J, McDowell CD, Shivanna V, et al.. Comparative evaluation of pathogenicity of three isolates of vesicular stomatitis virus (Indiana serotype) in pigs.. Journal of General Virology. 2019. DOI: https://doi.org/10.1099/jgv.0.001329

[32] Doerksen T, Bird E, Henningson J, Palinski RM. Near-Complete Genome Sequences of Vesicular Stomatitis Virus Isolates from the 2020 Outbreak in Kansas. Microbiology Resource Announcements. 2021. DOI: https://doi.org/10.1128/MRA.01454-20

[33] Sun C, Zhao K, Chen K, He W, Su G, Sun X, et al.. Development of a convenient immunochromatographic strip for the diagnosis of vesicular stomatitis virus serotype Indiana infections.. Journal of Virological Methods. 2013. DOI: https://doi.org/10.1016/j.jviromet.2012.12.003

[34] Ожерелков С, Ozherelkov S, Кожевникова Т, Kozhevnikova TN, Санин А, Sanin A, et al.. Study of Glutoxim antiviral activity in the fibroblast cell line infected with vesicular stomatitis virus. Russian veterinary journal. 2018. DOI: https://doi.org/10.32416/ARTICLE_5C050AC0894B34.21127720